12:00 AM
May 27, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Afatinib: Phase III data

The open-label, Asian Phase III LUX-Lung 6 trial in 364 patients with EGFR mutation-positive stage IIIb/IV NSCLC showed that once-daily 40 mg oral afatinib as first-line treatment met the primary endpoint of improving median PFS vs. gemcitabine plus cisplatin as assessed by both an independent review (11 vs. 5.6 months, p<0.0001) and the investigator review (13.7 vs. 5.6 months, p<0.0001). Afatinib...

Read the full 284 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >